<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>363</serviceExecutionTime><Drug id="66004"><DrugName>buprenorphine + naloxone (high dose, buccal (BEMA), opioid dependence), BioDelivery Sciences</DrugName><DrugNamesKey><Name id="43004442">Bunavail</Name></DrugNamesKey><DrugSynonyms><Name><Value>buprenorphine + naloxone</Value></Name><Name><Value>buprenorphine + naloxone (high dose, buccal (BEMA), opioid dependence), BioDelivery Sciences</Value></Name><Name><Value>BNX</Value></Name><Name><Value>Bunavail</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>BEMA Buprenorphine NX</Value></Name><Name><Value>52485-79-7</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>465-65-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="21164">BioDelivery Sciences International Inc</CompanyOriginator><CompaniesPrimary><Company id="21164">BioDelivery Sciences International Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="21164" type="Company"><TargetEntity id="4295902047" type="organizationId">BioDelivery Sciences International Inc</TargetEntity></SourceEntity><SourceEntity id="243" type="ciIndication"><TargetEntity id="F11.2" type="ICD10"></TargetEntity><TargetEntity id="D009293" type="MeSH"></TargetEntity><TargetEntity id="-1731206897" type="omicsDisease"></TargetEntity><TargetEntity id="1154" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="55116" type="Action"><TargetEntity id="2269" type="Mechanism">mu-Opioid Partial Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-01361" type="ciTarget"><TargetEntity id="43836512449883" type="siTarget">Mu-type opioid receptor</TargetEntity><TargetEntity id="1032" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Opiate dependence - US - Nov-2014</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="243">Opiate dependence</Indication></IndicationsPrimary><ActionsPrimary><Action id="55116">Opioid receptor mu partial agonist</Action></ActionsPrimary><Technologies><Technology id="175">Drug combination</Technology><Technology id="606">Transmucosal formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="680">Buccal formulation systemic</Technology><Technology id="662">Quick release formulation</Technology></Technologies><LastModificationDate>2019-04-05T09:51:06.000Z</LastModificationDate><ChangeDateLast>2018-06-28T00:00:00.000Z</ChangeDateLast><AddedDate>2010-04-01T16:23:55.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="21164" linkType="Company"&gt;BioDelivery Sciences&lt;/ulink&gt; has developed and launched a sublingual high-dose formulation of &lt;ulink linkID="2695" linkType="Drug"&gt;buprenorphine&lt;/ulink&gt; and naloxone (BNX; Bunavail; BEMA Buprenorphine NX), based on its buccal BEMA bioerodible polymer film technology. The product is indicated in the US   for the treatment of opioid dependence [&lt;ulink linkID="1997883" linkType="Reference"&gt;1997883&lt;/ulink&gt;].  In March 2018, the company was seeking to outlicense the product outside the US [&lt;ulink linkID="2015082" linkType="Reference"&gt;2015082&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2014, the drug was launched in the US for the maintenance treatment of opioid dependence [&lt;ulink linkID="1607874" linkType="Reference"&gt;1607874&lt;/ulink&gt;]; in May 2017, an sNDA was approved by the FDA revising the indication to include the use of Bunavail for the initiation of buprenorphine treatment for opioid dependence [&lt;ulink linkID="1923023" linkType="Reference"&gt;1923023&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company also markets a &lt;ulink linkID="54734" linkType="Drug"&gt;BEMA buprenorphine&lt;/ulink&gt; formulation.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In April 2012, the USPTO granted &lt;ulink linkID="PA6618268" linkType="Patent"&gt;US-08147866&lt;/ulink&gt;, which extended the exclusivity of the BEMA drug delivery technology from 2020 to 2027. In April 2014, the USPTO granted &lt;ulink linkID="PA7293185" linkType="Patent"&gt;US-08703177&lt;/ulink&gt;, which extended the exclusivity of the BEMA technology to at least 2032 [&lt;ulink linkID="1682605" linkType="Reference"&gt;1682605&lt;/ulink&gt;]. In December 2016,  the USPTO issued &lt;ulink linkID="PA3516917" linkType="Patent"&gt;US-09522188&lt;/ulink&gt; (expiring in December 2026), which was listed in the Orange Book as covering Bunavail  [&lt;ulink linkID="1909551" linkType="Reference"&gt;1909551&lt;/ulink&gt;]. In May 2017, the USPTO issued &lt;ulink linkID="PA9046105" linkType="Patent"&gt;US-09655843&lt;/ulink&gt; (expiring in July 2031), which was listed in the Orange Book as covering Bunavail  [&lt;ulink linkID="2015082" linkType="Reference"&gt;2015082&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2016, Actavis Laboratories (now &lt;ulink linkID="20348" linkType="Company"&gt;Teva&lt;/ulink&gt;) filed a Paragraph IV certification for a generic version of Bunavail, challenging &lt;ulink linkID="PA3000069" linkType="Patent"&gt;US-07579019&lt;/ulink&gt;, &lt;ulink linkID="PA6618268" linkType="Patent"&gt;US-08147866&lt;/ulink&gt; and &lt;ulink linkID="PA7293185" linkType="Patent"&gt;US-08703177&lt;/ulink&gt; [&lt;ulink linkID="1742522" linkType="Reference"&gt;1742522&lt;/ulink&gt;], [&lt;ulink linkID="1909551" linkType="Reference"&gt;1909551&lt;/ulink&gt;].  In March 2016, BioDelivery filed against Actavis, thus staying final approval of the ANDA until  at least August  2018. In February 2017, Actavis added &lt;ulink linkID="PA3516917" linkType="Patent"&gt;&lt;/ulink&gt;US-09522188 to its ANDA; BioDelivery planned to add the patent to its litigation against the ANDA. In January 2017, BioDelivery received notification from Teva, which had  acquired Actavis, of a Paragraph IV certification on additional strengths of Bunavail [&lt;ulink linkID="1909551" linkType="Reference"&gt;1909551&lt;/ulink&gt;]. In March 2017, BioDelivery filed suit  [&lt;ulink linkID="2015082" linkType="Reference"&gt;2015082&lt;/ulink&gt;]. In October 2017, BDSI entered into a settlement agreement with Teva that resolved the patent litigation. As a part of the settlement agreement, BDSI would enter into a non-exclusive license agreement with Teva to sell its generic version of Bunavail in the US on July 23, 2028 or earlier under certain circumstances [&lt;ulink linkID="1970502" linkType="Reference"&gt;1970502&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In September 2014, &lt;ulink linkID="29074" linkType="Company"&gt;Reckitt Benckiser&lt;/ulink&gt;, RB Pharmaceuticals and &lt;ulink linkID="1008765" linkType="Company"&gt;MonoSol&lt;/ulink&gt; (now Aquestive) filed suit against BioDelivery, alleging that Bunavail infringed &lt;ulink linkID="PA3505634" linkType="Patent"&gt;US-08765167&lt;/ulink&gt;. In October 2014, BioDelivery filed multiple IPR requests on the patent, and in December 2014, it filed a motion to dismiss the case [&lt;ulink linkID="1682605" linkType="Reference"&gt;1682605&lt;/ulink&gt;]. In July 2015, the court denied the motion to dismiss. By March 2016, the USPTO had instituted three of the four IPR requests; BioDelivery  had requested a  rehearing on the fourth  IPR [&lt;ulink linkID="1742522" linkType="Reference"&gt;1742522&lt;/ulink&gt;]. In March 2016, the final decisions was issued, finding all claims patentable; in April 2016, BioDelivery  filed a request for reconsideration in the USPTO. In May 2016, BioDelivery's motion to stay the case was granted until final resolution of the US-08765167 IPRs in the USPTO. In September 2016, the request for reconsideration was denied; BioDelivery appealed in November 2016, and the appeal brief was due in March 2017 [&lt;ulink linkID="1909551" linkType="Reference"&gt;1909551&lt;/ulink&gt;]. In March 2018, the appeal was proceeding and a decision expected in 2018  [&lt;ulink linkID="2015082" linkType="Reference"&gt;2015082&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, MonoSol filed a Petition for IPR on &lt;ulink linkID="PA3000069" linkType="Patent"&gt;US-07579019&lt;/ulink&gt;, which was instituted in August 2014. In August 2015, a decision upholding all seven claims was issued,  and in September 2015, MonoSol requested that the USPTO rehear the IPR  [&lt;ulink linkID="1742522" linkType="Reference"&gt;1742522&lt;/ulink&gt;]. In December 2016, a final decision denying MonoSol's request was denied;  MonoSol did not appeal the decision [&lt;ulink linkID="1909551" linkType="Reference"&gt;1909551&lt;/ulink&gt;]. By February 2017, MonoSol had not appealled the PTAB's final decision regarding the '019 patent  and the PTAB’s decision upholding all claims of ‘019 patent would be final and unappealable [&lt;ulink linkID="1909551" linkType="Reference"&gt;1909551&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In October 2013,  Reckitt Benckiser, RB Pharmaceuticals and MonoSol filed suit against BioDelivery, alleging that Bunavail infringed &lt;ulink linkID="PA6345423" linkType="Patent"&gt;US-08475832&lt;/ulink&gt;. In May 2014, the court granted BioDelivery's motion to dismiss and by June 2014, the RB plaintiffs did not appeal and lost the ability to appeal in future. In September 2014, BioDelivery filed a declaratory judgment action requesting the Court to make a determination that Bunavail did not infringe the RB Plaintiffs’ ‘832 patent, &lt;ulink linkID="PA5568210" linkType="Patent"&gt;US-07897080&lt;/ulink&gt;  and &lt;ulink linkID="PA7672263" linkType="Patent"&gt;US-08652378&lt;/ulink&gt;. In June 2015, all challenged claims were rejected for the '832 patent for both anticipation and obviousness. In August 2015, the RB Plaintiffs filed an appeal. The Federal Circuit affirmed the USPTO’s decision, and the RB Plaintiffs then filed a Petition for Panel Rehearing and for Rehearing En Banc, which was denied and a mandate was issued in October 2016, that meant that a petition for certiorari to the Supreme Court was no longer possible for the RB Plaintiffs; the ‘832 IPR was resolved with the invalidation of claims 15 to 19. For the ‘080 patent, all claims were  rejected in an inter partes reexamination and the rejection of all claims as invalid over the prior art was affirmed on appeal by the PTAB in March 2015. In May 2015, the RB Plaintiffs filed a response and BioDelivery filed comments. In December 2015, the PTAB denied Aquestive’s request to reopen prosecution. Later that month, Aquestive filed a request for a corrected response to which BioDelivery filed comments. In July 2016, the PTAB denied Aquestive’s request to reopen prosecution of the rejections of all claims over the prior art. In January 2017, the PTAB issued a final decision maintaining an additional new ground of rejection in addition to the previous grounds of invalidity. For the ‘378 Patent, an IPR was filed in June 2014. In November 2014, the PTAB decided not to institute the IPR was not instituted thereby construing the claims of the ‘378 patent narrowly. In December 2014, BioDelivery filed a motion to withdraw the ‘378 patent from the case and filed a joint motion to continue the stay (with RB Plaintiffs) in the proceedings, and both the motion to withdraw the ‘378 patent from the proceedings and motion to continue the stay were granted [&lt;ulink linkID="1909551" linkType="Reference"&gt;1909551&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In March 2011, the company reported the outcome of a pre-IND meeting with the FDA, confirming that NDA filing could be via the 505(b)(2)  regulatory pathway [&lt;ulink linkID="1172329" linkType="Reference"&gt;1172329&lt;/ulink&gt;]. By February 2012, the company had met with the FDA and discussed the results of  BNX-102 and development plan including BNX-103 and a supporting safety study. The FDA agreed to the plan while requesting an additional, non-comparative pharmacokinetic study examining the effects of multiple Bunavail films administered concurrently [&lt;ulink linkID="1267133" linkType="Reference"&gt;1267133&lt;/ulink&gt;]. In June 2013, a pre-NDA meeting was held with the FDA [&lt;ulink linkID="1436246" linkType="Reference"&gt;1436246&lt;/ulink&gt;]. In July 2013,   BioDelivery filed an NDA for the maintenance treatment of opioid dependence [&lt;ulink linkID="1459728" linkType="Reference"&gt;1459728&lt;/ulink&gt;]. In October 2013, the NDA was accepted for review by the FDA [&lt;ulink linkID="1485943" linkType="Reference"&gt;1485943&lt;/ulink&gt;].  In November 2013, the PDUFA date was set as June 07, 2014 [&lt;ulink linkID="1498954" linkType="Reference"&gt;1498954&lt;/ulink&gt;].   In June 2014, the drug  was approved by the  FDA for the maintenance treatment of opioid dependence [&lt;ulink linkID="1566647" linkType="Reference"&gt;1566647&lt;/ulink&gt;]. In November 2014, the drug was launched [&lt;ulink linkID="1607874" linkType="Reference"&gt;1607874&lt;/ulink&gt;]. In October 2015, the FDA approved an sNDA for a manufacturing specification change for immediate-release Bunavail [&lt;ulink linkID="1703430" linkType="Reference"&gt;1703430&lt;/ulink&gt;]. In May 2017, an sNDA was approved by the FDA revising the indication to include the use of Bunavail for the initiation of buprenorphine treatment for opioid dependence [&lt;ulink linkID="1923023" linkType="Reference"&gt;1923023&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In March 2016, the company noted that the approval of the drug carried a standard post-approval requirement by the FDA to conduct a study to determine the effect on QT prolongation [&lt;ulink linkID="1742522" linkType="Reference"&gt;1742522&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In August 2015, a randomized, double blind, active controlled, phase III trial (&lt;ulink linkID="238197" linkType="Protocol"&gt;NCT02516436&lt;/ulink&gt;; BNX-302) of Bunavail versus buprenorphine was to be initiated in the US to assess the safety of the drug in opioid dependent subjects (expected n = 40). However, by May 2017, the trial was withdrawn as the FDA did not require a clinical trial for the indication [&lt;ulink linkID="1997901" linkType="Reference"&gt;1997901&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, a randomized, double-blind, placebo-controlled, phase III trial (&lt;ulink linkID="95914" linkType="Protocol"&gt;NCT01713803&lt;/ulink&gt;; BNX-350) was to be initiated in the US in opioid dependent subjects. However, by February 2015, the trial was withdrawn as the FDA did not require a clinical trial for the indication [&lt;ulink linkID="1997903" linkType="Reference"&gt;1997903&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In August 2012, an open-label, phase II trial (&lt;ulink linkID="90253" linkType="Protocol"&gt;NCT01666119&lt;/ulink&gt;; BNX-201) was initiated in the US to assess the safety and tolerability of Bunavail in opioid dependent subjects (n = 249) stabilized on &lt;ulink linkID="75426" linkType="Drug"&gt;Suboxone&lt;/ulink&gt; tablets or films. The primary endpoint was adverse events  [&lt;ulink linkID="1997904" linkType="Reference"&gt;1997904&lt;/ulink&gt;]. In January 2013, the study, at that time referred to as phase III,  was completed and the drug was found to be well tolerated [&lt;ulink linkID="1358754" linkType="Reference"&gt;1358754&lt;/ulink&gt;], [&lt;ulink linkID="1566647" linkType="Reference"&gt;1566647&lt;/ulink&gt;]. In November 2014, data were reported, showing the drug  had favorable safety and efficacy with a high study retention rate and  low frequency of patients with positive urine tests for non-prescribed opioids over the 12-week period [&lt;ulink linkID="1607874" linkType="Reference"&gt;1607874&lt;/ulink&gt;]. In March 2018, further data were reported showing that over 91% of patients who switched from Suboxone film or tablets to Bunavail considered the taste of Bunavail to be very pleasant, pleasant or neutral and over 82% rated the ease of use of Bunavailas very easy, easy or neutral. There was also a decrease in the incidence of constipation symptoms from 41% at baseline, before conversion of patients from Suboxone tablets or films to Bunavail, to 13% following 12 weeks of treatment with Bunavail [&lt;ulink linkID="2015082" linkType="Reference"&gt;2015082&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In February 2012, the company was planning to initiate an additional, non-comparative pharmacokinetic study examining the effects of multiple Bunavail films administered concurrently  as requested by the FDA [&lt;ulink linkID="1267133" linkType="Reference"&gt;1267133&lt;/ulink&gt;]. In June 2012, data were reported from the BNX-106 study. Data confirmed that the pharmacokinetics of buprenorphine were nearly identical after multiple Bunavail films were applied at one time, compared with an equivalent dose given as a single film. When Bunavail doses were increased, a corresponding increase of buprenorphine in the plasma was found. It was demonstrated that the naloxone exposure was similar to &lt;ulink linkID="75426" linkType="Drug"&gt;Suboxone&lt;/ulink&gt;, the reference standard. Data demonstrated the dose proportionality ahead of the upcoming pivotal pharmacokinetic study [&lt;ulink linkID="1304936" linkType="Reference"&gt;1304936&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2011, a pivotal bioequivalence   trial (BNX-103) was planned [&lt;ulink linkID="1220154" linkType="Reference"&gt;1220154&lt;/ulink&gt;]. The pivotal pharmacokinetic study would compare the drug with Suboxone in normal volunteers  [&lt;ulink linkID="1267133" linkType="Reference"&gt;1267133&lt;/ulink&gt;]. In August 2012, enrollment was completed and all the subjects had been dosed  [&lt;ulink linkID="1316724" linkType="Reference"&gt;1316724&lt;/ulink&gt;]. In September 2012, data from the study were reported demonstrating maximum drug plasma concentration (Cmax) and total drug exposure (AUC), for which buprenorphine was comparable to Suboxone and naloxone was similar or less than Suboxone. The study met its endpoints [&lt;ulink linkID="1323292" linkType="Reference"&gt;1323292&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011,  a  confirmatory pharmacokinetic study  (BNX-102) of the combination in comparison with Suboxone  (buprenorphine plus naloxone) was initiated. The study was to determine a dose for   a bioequivalence study 	   [&lt;ulink linkID="1238363" linkType="Reference"&gt;1238363&lt;/ulink&gt;]. In December 2011, results showed the formulation and dose selection provided comparable exposure of both  drugs compared with Suboxone [&lt;ulink linkID="1250265" linkType="Reference"&gt;1250265&lt;/ulink&gt;]. By February 2012, the study had been completed [&lt;ulink linkID="1267133" linkType="Reference"&gt;1267133&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2011, BioDelivery reported positive pharmacokinetic data from a phase I trial (BNX-101) of the combination in comparison with Suboxone. The BEMA formulation delivered plasma concentrations of buprenorphine in the effective treatment range while minimizing naloxone  exposure  [&lt;ulink linkID="1220154" linkType="Reference"&gt;1220154&lt;/ulink&gt;], [&lt;ulink linkID="1238363" linkType="Reference"&gt;1238363&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="21164">BioDelivery Sciences International Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-11-03T00:00:00.000Z</StatusDate><Source id="1607874" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="21164">BioDelivery Sciences International Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-09-06T00:00:00.000Z</StatusDate><Source id="1220154" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21164">BioDelivery Sciences International Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-18T00:00:00.000Z</StatusDate><Source id="1306667" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21164">BioDelivery Sciences International Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-31T00:00:00.000Z</StatusDate><Source id="1459728" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21164">BioDelivery Sciences International Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-06-06T00:00:00.000Z</StatusDate><Source id="1566647" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21164">BioDelivery Sciences International Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="243">Opiate dependence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-02-26T00:00:00.000Z</StatusDate><Source id="1077722" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01361"><Name>Opioid receptor mu</Name><SwissprotNumbers><Swissprot>P33535</Swissprot><Swissprot>P35372</Swissprot><Swissprot>P42866</Swissprot><Swissprot>P79350</Swissprot><Swissprot>P97266</Swissprot><Swissprot>Q5IS39</Swissprot><Swissprot>Q95247</Swissprot><Swissprot>Q95M54</Swissprot><Swissprot>Q9MYW9</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2089713" linkType="reference" linkID="2089713"&gt;2089713&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009670">Sharp Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1040021">CVS Caremark</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1101929">IQVIA Holdings Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21164">BioDelivery Sciences International Inc</Company><CountAsPrincipalActive>3</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>3</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>5</CountTotal></Company><Company><Company id="DOL1000194">Adhesives Research Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="12">Patent - Non-Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3Cc6c5c(c(cc6)O)O4)CC7CC7)OC)(C(C)(C)C)O</Smiles><Smiles>C=CCN1CC[C@]23c4c5ccc(c4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)O</Smiles><Smiles>C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3Cc6c5c(c(cc6)O)O4)CC7CC7)OC)(C(C)(C)C)O.C=CCN1CC[C@]23c4c5ccc(c4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)O</Smiles></StructureSmiles><Deals><Deal id="148916" title="Quintiles to support US launch of BioDelivery Sciences' BUNAVAIL for opioid dependence "></Deal><Deal id="240838" title="CVS Caremark to distribute BioDelivery Sciences' Belbuca and Bunavail in the US"></Deal><Deal id="246115" title="Teva and BioDelivery Sciences to settle patent litigation on Bunavail  "></Deal><Deal id="248181" title="Sharp to pack dosage units and supply finished Bunavail to BioDelivery Sciences"></Deal><Deal id="248182" title="ARx to supply Bunavail to BioDelivery Sciences in the US "></Deal></Deals><PatentFamilies><PatentFamily id="1060125" number="WO-09955312" title="Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces"></PatentFamily><PatentFamily id="127763" number="WO-09817251" title="Pharmaceutical Carrier Device Suitable For Delivery Of Pharmaceutical Compounds To Mucosal Surfaces"></PatentFamily><PatentFamily id="2106987" number="WO-2007070632" title="Abuse resistant transmucosal drug delivery device"></PatentFamily><PatentFamily id="2472694" number="WO-2013026064" title="Abuse-resistant mucoadhesive devices for delivery of buprenorphine"></PatentFamily><PatentFamily id="69452" number="WO-2008011194" title="Transmucosal delivery devices with enhanced uptake"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aquestive Therapeutics Inc" id="1008765"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="TOLMAR Holding Inc" id="1050057"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alvogen Inc" id="1051273"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novelion Therapeutics Inc" id="19180"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>5</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BioDelivery Sciences International Inc" id="21164"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Collegium Pharmaceutical Inc" id="30003"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>